The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Table 1

Baseline characteristics of the included studies.

Author	Year	Age	Region	Cancer type	ICI treatment	PPI treatment	No. of PPI	Patients	PPI exposure
Chalabi et al. [30]	2020	NA	Worldwide	NSCLC	PD-L1	Omeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole, dexlansoprazole	234	757	Prior, within (30 days)
Hakozaki et al. [31]	2019	67	Asia	NSCLC	PD-1	NA	47	90	Prior (30 days)
Svaton et al. [32]	2020	67	Europe	NSCLC	PD-1	Omeprazole, pantoprazole, lansoprazole	64	224	Prior, within (30 days)
Zhao et al. [33]	2019	62	Asia	NSCLC	PD-1, other	NA	40	109	Prior, within (30 days)
Stokes et al. [34]	2021	69	America	NSCLC	PD-(L)1	Omeprazole (majority)	2159	3634	Within (90 days)
Miura et al. [35]	2021	65	Asia	NSCLC	PD-1	Lansoprazole, rabeprazole, Esomeprazole	163	300	Within
Cortellini et al. [36]	2021	70.1	Europe	NSCLC	PD-L1	NA	474	950	Prior, within (30 days)
Giordan et al. [29]	2021	63.9	Worldwide	NSCLC	PD-(L)1	Pantoprazole, esomeprazole, lansoprazole, Rabeprazole, omeprazole	47	212	Prior (30 days)
Hopkins et al. [37]	2022	NA	Oceania	NSCLC	PD-(L)1	NA	441	1202	Prior, within (30 days)
Hopkins et al. [38]	2022	NA	Oceania	NSCLC	PD-L1	Omeprazole,pantoprazole, esomeprazole, lansoprazole, rabeprazole, dexlansoprazole, vanoprazan	1225	4458	Within
Husain et al. [39]	2021	NA	America	NSCLC	PD-(L)1	NA	149	415	Within

NSCLC, non-small cell lung cancer; PPI, proton pump inhibitor; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand 1; NA, not available; ICI, immune checkpoint inhibitor.